The joint research of the Finlay Vaccine Institute and the Amedeo di Savoia Hospital in Turin includes people immunized with vaccines authorized in the European Union such as Pfizer, Moderna, AstraZeneca and Johnson & Johnson, who will receive Cuba’s Soberana Plus as a third dose.
Participants in the study will receive the booster dose of the drug developed by the Finlay Vaccine Institute before returning to Italy, where they will undergo blood tests to measure the specific antibody response, 28 days after being vaccinated, according to a communique released by the Turin-based medical center.
Upon referring to the “prestigious bilateral collaboration between Italy and Cuba,” the text highlighted the role played by the Agency for Cultural and Economic Exchange with Cuba (AICEC), and the Italian Embassy in Havana and Cuban Embassy in Rome in the completion of the agreement.
Soberana Plus, the document stated, is the only vaccine developed globally, since the beginning, designed to use as a booster dose for persons already immunized with other vaccines or to strengthen immunization in people who have overcome the disease.
jg/iff/mem/fgg
